Company Overview
Mesoblast Limited operates within the healthcare sector, specifically the biotechnology industry, focusing on the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland. The company's proprietary technology platform relies on specialized cells known as mesenchymal lineage to advance its product pipeline. With a market capitalization of $1.91B, the company has established itself as a significant entity in the biotech landscape, employing a workforce of 81 individuals to drive its research and development efforts. The annual revenue of $65.38M, combined with its substantial market cap, indicates that the company commands a high valuation relative to its current sales output, a characteristic often found in capital-intensive biotechnology firms where future potential outweighs current profitability.
Financial Health
Mesoblast Limited reported revenue of $65.38M for the trailing twelve months, yet posted a net income of $-94,370,000 and an EBITDA of $-64,339,000. The substantial gap between the positive revenue figure and the significantly larger negative net income reveals a cost structure characterized by high operating expenses that exceed gross revenue generation. The company generated a free cash flow of $-69,438,336, which indicates a negative cash conversion where outflows for operations and capital expenditures exceed cash inflows from sales. This negative free cash flow suggests the company is currently burning cash, a common phase for biotech firms investing heavily in clinical trials and platform development before achieving commercial scale. The gross margin stands at -35.5%, while the operating margin is -55.2% and the profit margin reaches -144.3%; these deeply negative figures indicate that the cost of goods sold and operating expenses are far exceeding revenue, resulting in a loss on every dollar of sales. On the balance sheet, the company holds $129.97M in cash against $135.14M in debt, resulting in a debt-to-equity ratio of 23.52. This ratio implies a leveraged balance sheet where debt obligations slightly exceed liquid cash reserves, though the negative earnings contribute to the equity base. The current ratio of 1.58 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, suggesting a baseline level of liquidity despite the cash burn. Furthermore, the return on equity is -18.2% and the return on assets is -6.2%, metrics that reveal that management is currently generating negative returns on both shareholder equity and the total asset base utilized to generate revenue.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is -71.80; the difference between a non-existent trailing multiple and a negative forward multiple implies that earnings are currently negative and future earnings projections have not yet turned positive to support a traditional valuation multiple. The price-to-book ratio is 32.20, a figure that indicates the market is valuing the company at a massive premium over its tangible book value, reflecting high expectations for the value of its intellectual property and pipeline assets. Additional valuation metrics include a price-to-sales ratio of 29.14 and an EV/EBITDA of -287.67, which suggest that the market is pricing the stock based on revenue potential rather than current earnings power or cash flow generation. The 52-week high is $21.50 and the 52-week low is $9.61, placing the stock's recent trading activity within a wide historical range that reflects significant price volatility. The beta value of 0.85 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it moves with a degree of stability relative to the overall index despite its high valuation multiple.
Growth & Income
Mesoblast Limited demonstrated a revenue growth year-over-year of 1526.8%, while earnings growth year-over-year is N/A due to the company's continued losses. The earnings growth rate cannot be calculated as a percentage increase because the earnings are negative, implying that revenue growth is occurring without a corresponding improvement in profitability yet. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available capital and earnings back into its regenerative medicine platform rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage biotechnology companies that prioritize funding clinical development and regulatory milestones over providing current income to investors. The overall growth and income profile is defined by explosive revenue expansion coupled with persistent financial losses and a complete absence of dividend distributions.